

Appendix 3: Characteristics of cases and controls in matched subset for sensitivity analysis

Variable	Cases (n = 148)	Controls (n = 231)	Standardized difference*
Age, yr, median (IQR)	86 (81–90)	86 (80–90)	0.08
66–74	15 (10.1)	30 (13.0)	0.01
75–84	37 (25.0)	58 (25.1)	0.06
≥ 85	96 (64.9)	143 (61.9)	0.07
Female sex, no. (%)	104 (70.3)	170 (73.6)	0.07
No. of years using spironolactone, median (IQR)	1 (0–2)	2 (1–3)	0.48
Charlson Comorbidity Index, no. (%)			
No hospital admission	30 (20.3)	57 (24.7)	0.1
0	12 (8.1)	22 (9.5)	0.05
1	30 (20.3)	35 (15.2)	0.14
≥ 2	76 (51.4)	117 (50.6)	0.01
Comorbidity in past 3 years, no. (%)			
Angina	≤ 5†	≤ 5†	0.02
Acute myocardial infarction	9 (6.1)	12 (5.2)	0.04
Dysrhythmia	56 (37.8)	86 (37.2)	0.01
Chronic kidney disease	≤ 5†	≤ 5†	0.01
Congestive heart failure, no. (%)	104 (70.3)	155 (67.1)	0.07
Diabetes mellitus, no. (%)	≤ 5†	≤ 5†	0.06
Hypertension, no. (%)	116 (78.4)	185 (80.1)	0.04
Residence in a long-term care facility, no. (%)	75 (50.7)	129 (55.8)	0.1
Number of prescription drugs in previous year, median (IQR)	17 (13–21)	17 (13–21)	0.05
Medication use in preceding 90 days, no. (%)			
Non-potassium-sparing diuretic	121 (81.8)	202 (87.4)	0.16
Potassium-sparing diuretic	≤ 5†	≤ 5†	0.00
β-Adrenergic receptor antagonist	61 (41.2)	85 (36.8)	0.09
Potassium supplement	≤ 5†	9 (3.9)	0.03
NSAID	22 (14.9)	26 (11.3)	0.11
Renin-angiotensin-aldosterone inhibitor	76 (51.4)	117 (50.6)	0.01
Income quintile, no. (%)			
1 (lowest)	38 (25.7)	56 (24.2)	0.03
2	33 (22.3)	41 (17.7)	0.11
3	20 (13.5)	44 (19.0)	0.15
4	28 (18.9)	59 (25.5)	0.16
5 (highest)	26 (17.6)	30 (13.0)	0.13
Note: IQR = interquartile range, NSAID = nonsteroidal anti-inflammatory drug. *Difference between cases and controls divided by standard deviation. †Prevalence not reported because of small cell size			